GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Theragen Etex Co Ltd (XKRX:066700) » Definitions » Debt-to-EBITDA

Theragen Etex Co (XKRX:066700) Debt-to-EBITDA : -0.25 (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Theragen Etex Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Theragen Etex Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩47,787 Mil. Theragen Etex Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩2,689 Mil. Theragen Etex Co's annualized EBITDA for the quarter that ended in Dec. 2024 was ₩-202,151 Mil. Theragen Etex Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.25.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Theragen Etex Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:066700' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -24.66   Med: -0.36   Max: 7.41
Current: -1.47

During the past 13 years, the highest Debt-to-EBITDA Ratio of Theragen Etex Co was 7.41. The lowest was -24.66. And the median was -0.36.

XKRX:066700's Debt-to-EBITDA is ranked worse than
100% of 675 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs XKRX:066700: -1.47

Theragen Etex Co Debt-to-EBITDA Historical Data

The historical data trend for Theragen Etex Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theragen Etex Co Debt-to-EBITDA Chart

Theragen Etex Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.66 -6.18 1.54 0.89 -1.47

Theragen Etex Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 1.76 2.61 1.80 -0.25

Competitive Comparison of Theragen Etex Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Theragen Etex Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theragen Etex Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Theragen Etex Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Theragen Etex Co's Debt-to-EBITDA falls into.


;
;

Theragen Etex Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Theragen Etex Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(47787.409 + 2688.803) / -34386.545
=-1.47

Theragen Etex Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(47787.409 + 2688.803) / -202151.236
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Theragen Etex Co  (XKRX:066700) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Theragen Etex Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Theragen Etex Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Theragen Etex Co Business Description

Traded in Other Exchanges
N/A
Address
58, Sandan-ro 68-gil, Danwon-gu, Gyeonggi-do, Ansan-si, KOR
Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.

Theragen Etex Co Headlines

No Headlines